DE2555169C2 - - Google Patents
Info
- Publication number
- DE2555169C2 DE2555169C2 DE2555169A DE2555169A DE2555169C2 DE 2555169 C2 DE2555169 C2 DE 2555169C2 DE 2555169 A DE2555169 A DE 2555169A DE 2555169 A DE2555169 A DE 2555169A DE 2555169 C2 DE2555169 C2 DE 2555169C2
- Authority
- DE
- Germany
- Prior art keywords
- hepatitis
- antigen
- liver
- suspension
- approximately
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 208000005252 hepatitis A Diseases 0.000 claims description 36
- 239000000427 antigen Substances 0.000 claims description 34
- 108091007433 antigens Proteins 0.000 claims description 34
- 102000036639 antigens Human genes 0.000 claims description 34
- 210000004185 liver Anatomy 0.000 claims description 18
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 claims description 15
- 241000709721 Hepatovirus A Species 0.000 claims description 11
- 238000004458 analytical method Methods 0.000 claims description 11
- AIYUHDOJVYHVIT-UHFFFAOYSA-M caesium chloride Chemical compound [Cl-].[Cs+] AIYUHDOJVYHVIT-UHFFFAOYSA-M 0.000 claims description 10
- 238000000034 method Methods 0.000 claims description 10
- 210000002966 serum Anatomy 0.000 claims description 8
- 239000000725 suspension Substances 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 7
- 239000000463 material Substances 0.000 claims description 5
- 239000002504 physiological saline solution Substances 0.000 claims description 5
- ODBLHEXUDAPZAU-ZAFYKAAXSA-N D-threo-isocitric acid Chemical compound OC(=O)[C@H](O)[C@@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-ZAFYKAAXSA-N 0.000 claims description 4
- 101710088194 Dehydrogenase Proteins 0.000 claims description 4
- 108090000790 Enzymes Proteins 0.000 claims description 4
- 102000004190 Enzymes Human genes 0.000 claims description 4
- ODBLHEXUDAPZAU-FONMRSAGSA-N Isocitric acid Natural products OC(=O)[C@@H](O)[C@H](C(O)=O)CC(O)=O ODBLHEXUDAPZAU-FONMRSAGSA-N 0.000 claims description 4
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims description 4
- 229930195712 glutamate Natural products 0.000 claims description 4
- 208000006454 hepatitis Diseases 0.000 claims description 4
- 231100000283 hepatitis Toxicity 0.000 claims description 4
- KHPXUQMNIQBQEV-UHFFFAOYSA-N oxaloacetic acid Chemical compound OC(=O)CC(=O)C(O)=O KHPXUQMNIQBQEV-UHFFFAOYSA-N 0.000 claims description 4
- ODBLHEXUDAPZAU-UHFFFAOYSA-N threo-D-isocitric acid Natural products OC(=O)C(O)C(C(O)=O)CC(O)=O ODBLHEXUDAPZAU-UHFFFAOYSA-N 0.000 claims description 4
- 229960005486 vaccine Drugs 0.000 claims description 4
- 241000288906 Primates Species 0.000 claims description 3
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 3
- 239000011780 sodium chloride Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 230000000405 serological effect Effects 0.000 claims description 2
- 230000003053 immunization Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 230000000415 inactivating effect Effects 0.000 claims 1
- 230000002779 inactivation Effects 0.000 claims 1
- 238000004806 packaging method and process Methods 0.000 claims 1
- 230000003313 weakening effect Effects 0.000 claims 1
- 241000700605 Viruses Species 0.000 description 11
- 241001515942 marmosets Species 0.000 description 10
- 239000002245 particle Substances 0.000 description 8
- 230000000295 complement effect Effects 0.000 description 5
- 241000288956 Saguinus mystax Species 0.000 description 4
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 4
- 239000002953 phosphate buffered saline Substances 0.000 description 4
- 238000000926 separation method Methods 0.000 description 4
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000001493 electron microscopy Methods 0.000 description 3
- 239000000284 extract Substances 0.000 description 3
- 230000001900 immune effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 239000006228 supernatant Substances 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 241000288950 Callithrix jacchus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 208000037319 Hepatitis infectious Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000288954 Saguinus fuscicollis Species 0.000 description 2
- 241000288946 Saguinus nigricollis Species 0.000 description 2
- 241000288960 Saguinus oedipus Species 0.000 description 2
- 102000003929 Transaminases Human genes 0.000 description 2
- 108090000340 Transaminases Proteins 0.000 description 2
- 238000005352 clarification Methods 0.000 description 2
- 229910052802 copper Inorganic materials 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 229940124724 hepatitis-A vaccine Drugs 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 210000005228 liver tissue Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 241001201743 Aseptis Species 0.000 description 1
- 241000170006 Bius Species 0.000 description 1
- 241000288952 Callithrix argentata Species 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 241000282552 Chlorocebus aethiops Species 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241001243761 Human hepatitis A virus Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 241000282579 Pan Species 0.000 description 1
- 241000282577 Pan troglodytes Species 0.000 description 1
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-N Sulfurous acid Chemical compound OS(O)=O LSNNMFCWUKXFEE-UHFFFAOYSA-N 0.000 description 1
- 241001504501 Troglodytes Species 0.000 description 1
- COQLPRJCUIATTQ-UHFFFAOYSA-N Uranyl acetate Chemical compound O.O.O=[U]=O.CC(O)=O.CC(O)=O COQLPRJCUIATTQ-UHFFFAOYSA-N 0.000 description 1
- 235000013405 beer Nutrition 0.000 description 1
- HOQPTLCRWVZIQZ-UHFFFAOYSA-H bis[[2-(5-hydroxy-4,7-dioxo-1,3,2$l^{2}-dioxaplumbepan-5-yl)acetyl]oxy]lead Chemical compound [Pb+2].[Pb+2].[Pb+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HOQPTLCRWVZIQZ-UHFFFAOYSA-H 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 229910003460 diamond Inorganic materials 0.000 description 1
- 239000010432 diamond Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 239000003822 epoxy resin Substances 0.000 description 1
- 239000008098 formaldehyde solution Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229910000489 osmium tetroxide Inorganic materials 0.000 description 1
- 239000012285 osmium tetroxide Substances 0.000 description 1
- TWNQGVIAIRXVLR-UHFFFAOYSA-N oxo(oxoalumanyloxy)alumane Chemical compound O=[Al]O[Al]=O TWNQGVIAIRXVLR-UHFFFAOYSA-N 0.000 description 1
- IYDGMDWEHDFVQI-UHFFFAOYSA-N phosphoric acid;trioxotungsten Chemical compound O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.O=[W](=O)=O.OP(O)(O)=O IYDGMDWEHDFVQI-UHFFFAOYSA-N 0.000 description 1
- 229920000647 polyepoxide Polymers 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/576—Immunoassay; Biospecific binding assay; Materials therefor for hepatitis
- G01N33/5768—Hepatitis A
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Hematology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US05/530,623 US4029764A (en) | 1974-12-09 | 1974-12-09 | Hepatitis A antigen |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| DE2555169A1 DE2555169A1 (de) | 1976-06-10 |
| DE2555169C2 true DE2555169C2 (en:Method) | 1987-08-13 |
Family
ID=24114319
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DE19752555169 Granted DE2555169A1 (de) | 1974-12-09 | 1975-12-08 | Hepatitis-antigen |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US4029764A (en:Method) |
| JP (1) | JPS5182720A (en:Method) |
| BE (1) | BE836390A (en:Method) |
| CY (1) | CY1104A (en:Method) |
| DE (1) | DE2555169A1 (en:Method) |
| FR (1) | FR2293944A1 (en:Method) |
| GB (1) | GB1508878A (en:Method) |
| HK (1) | HK4081A (en:Method) |
| KE (1) | KE3110A (en:Method) |
| MY (1) | MY8100308A (en:Method) |
| NL (1) | NL189050C (en:Method) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4296024A (en) * | 1974-12-09 | 1981-10-20 | Merck & Co., Inc. | Human immune serum globulin with high hepatitis A antibody titer |
| US4017601A (en) * | 1975-10-16 | 1977-04-12 | Merck & Co., Inc. | Hepatitis A antigen |
| JPS5283929A (en) * | 1976-01-01 | 1977-07-13 | Merck & Co Inc | Hepatisis a antigen |
| NL7711378A (nl) * | 1976-11-02 | 1978-05-05 | Merck & Co Inc | Werkwijze voor het bereiden van preparaten die dane-deeltjes bevatten. |
| GB1554811A (en) * | 1977-02-23 | 1979-10-31 | Merck & Co Inc | Purifying hepatitis b surface antigen |
| US4164566A (en) * | 1978-08-17 | 1979-08-14 | Merck & Co., Inc. | Hepatitis a virus cell culture in vitro |
| US4181713A (en) * | 1978-10-30 | 1980-01-01 | Merck & Co., Inc. | Isolation of HBs Ag |
| US4395395A (en) * | 1979-05-21 | 1983-07-26 | The United States Of America As Represented By The Department Of Health And Human Services | Detection of non-A, non-B hepatitis associated antigen |
| CA1164799A (en) | 1979-09-04 | 1984-04-03 | Paula A. Giesa | Cell culture of hepatitis a virus |
| US5514376A (en) * | 1979-09-04 | 1996-05-07 | Merck & Co., Inc. | Cell culture of hepatitis A virus |
| JPS63246335A (ja) * | 1987-09-17 | 1988-10-13 | メルク エンド カムパニー インコーポレーテツド | 肝炎ｂ抗原 |
| HRP950097A2 (en) | 1994-03-08 | 1997-06-30 | Merck & Co Inc | Hepatitis a virus culture process |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3636191A (en) * | 1969-10-08 | 1972-01-18 | Cancer Res Inst | Vaccine against viral hepatitis and process |
| US3735004A (en) * | 1971-11-01 | 1973-05-22 | Us Army | Hepatitis vaccine |
| NL189051C (nl) * | 1974-12-09 | 1992-12-16 | Merck & Co Inc | Werkwijze voor het bepalen van antilichamen in een monster. |
-
1974
- 1974-12-09 US US05/530,623 patent/US4029764A/en not_active Expired - Lifetime
-
1975
- 1975-11-26 NL NLAANVRAGE7513816,A patent/NL189050C/xx not_active IP Right Cessation
- 1975-12-05 CY CY1104A patent/CY1104A/xx unknown
- 1975-12-05 GB GB50061/75A patent/GB1508878A/en not_active Expired
- 1975-12-05 FR FR7537267A patent/FR2293944A1/fr active Granted
- 1975-12-08 DE DE19752555169 patent/DE2555169A1/de active Granted
- 1975-12-08 BE BE162539A patent/BE836390A/xx not_active IP Right Cessation
- 1975-12-09 JP JP50146002A patent/JPS5182720A/ja active Granted
-
1981
- 1981-01-29 KE KE3110A patent/KE3110A/xx unknown
- 1981-02-04 HK HK40/81A patent/HK4081A/xx unknown
- 1981-12-30 MY MY308/81A patent/MY8100308A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MY8100308A (en) | 1981-12-31 |
| JPS5182720A (en) | 1976-07-20 |
| KE3110A (en) | 1981-02-20 |
| US4029764A (en) | 1977-06-14 |
| GB1508878A (en) | 1978-04-26 |
| JPS6335612B2 (en:Method) | 1988-07-15 |
| CY1104A (en) | 1981-09-11 |
| HK4081A (en) | 1981-02-13 |
| NL189050C (nl) | 1992-12-16 |
| BE836390A (fr) | 1976-06-08 |
| FR2293944A1 (fr) | 1976-07-09 |
| DE2555169A1 (de) | 1976-06-10 |
| NL7513816A (nl) | 1976-06-11 |
| FR2293944B1 (en:Method) | 1979-03-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE69327307T2 (de) | Herstellung von antigenen und impfstoffen vom mysterie-disease-virus, antigene und erworbene impfstoffe zur verhinderung dieser krankheit | |
| Schaffer et al. | Purification and properties of poliovirus | |
| DE2555169C2 (en:Method) | ||
| DE2049515A1 (de) | Impfstoff gegen Virushepatitis | |
| DE2516274C2 (de) | Verfahren zum Herstellen eines abgeschwächten Zytomegalie-Virus-Impfstoffes | |
| DE2621276C2 (en:Method) | ||
| DE1617940C2 (de) | Verfahren zur Gewinnung eines für die Züchtung von Viren geeigneten Zellstammes | |
| DE2713371A1 (de) | Impfstoff gegen die rhinotracheitis der katze und verfahren zu seiner herstellung | |
| DE2463143C2 (de) | Polyvalente Rindervirus-Lebendimpfstoffe | |
| DE69633233T2 (de) | Multivalenter impstoff gegen bovines coronavirus und methode zur behandlung einer infektion mit bovinem coronavirus | |
| DE2610717B2 (de) | Hepatitis-B-Impfstoff und Verfahren zu seiner Herstellung | |
| US4031203A (en) | Hepatitis A antigen | |
| DE2456636A1 (de) | Influenza-vakzine und verfahren zu ihrer herstellung | |
| DE2560402C2 (de) | Verfahren zur Herstellung von zur Therapie von Hepatitis A geeignetem, menschlichem Immunserumglobulin | |
| US2720484A (en) | Process for separation of viral substances from animal tissues | |
| DE2132911C2 (de) | Verfahren zum Herstellen eines stark abgeschwächte Rötelviren enthaltenden Impfstoffs | |
| DE3913438A1 (de) | Verfahren zum herstellen einer immunitaetsgedaechtniszellsuspension | |
| DE1007473B (de) | Verfahren zur Herstellung eines Poliomyelitis-Impfstoffes | |
| Jortner et al. | Experimental Chandipura virus infection in mice: I. Virus assay and light microscopic studies with emphasis on neuropathologic observations | |
| DE3779444T2 (de) | Impfstoff gegen herpes simplex. | |
| DE959048C (de) | Verfahren zur Herstellung eines Impfstoffes zur aktiven Schutzimpfung gegen spinale Kinderlaehmung | |
| DE1037655B (de) | Verfahren zur Herstellung von Impfloesungen mit abgetoetetem infektioesem Hepatitisvirus | |
| DE1037656B (de) | Verfahren zur Bestimmung ueberstandener oder akuter infektioeser Hepatitis sowie zur Bestimmung der Brauchbarkeit von y-Globulin zu ihrer Behandlung | |
| DE3150935A1 (de) | Verfahren zur herstellung eines hepatitis-b impfstoffes | |
| AT231068B (de) | Verfahren zur Herstellung von Vaccinzwischenprodukten |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| 8110 | Request for examination paragraph 44 | ||
| 8128 | New person/name/address of the agent |
Representative=s name: ABITZ, W., DIPL.-ING.DR.-ING. MORF, D., DR., PAT.- |
|
| D2 | Grant after examination | ||
| 8364 | No opposition during term of opposition |